An ISO 9001:2008 & GMP certified company  | info@arlakbiotech.com  |  +91-9803023099, 7696263636  |  1800-121-6263 (Toll Free) 

TEXAR-T INJ


COMPOSITION: CEFTRIAXONE 1000 MG TAZOBACTUM 125 MG

Categories: , .
Description

Pharmacology

  • Pharmacokinetics

Ceftriaxone interferes with the biosynthesis of the peptidoglycan component of the bacterial cell way by binding to and inactivating penicllin-binding proteins (PBPs). Tazobactam is a penicillanic acid sulfone derivative with β-lactamase inhibitory properties. It enhances the activity of β-lactam antibacterials against β-lactamase-producing bacteria.

          Distribution: – Ceftriaxone: 98% bound to plasma proteins; crosses the blood brain barrier. Tazobactam:About 30% bound to plasma proteins; widely distributed to tissues and body fluids.

          Excretion: – Ceftriaxone: Elimination half-life is about 8.7 hours; 33-67% removed as unchanged drug. Tazobactam: Removed mainly via kidneys with 80% of an administered dose as unchanged drug

 

  • Pharmacodynamics: – Ceftriaxone is a 3rd generation cephalosporin which exerts its bactericidal action against both gram positive & gram negative organisms by inhibiting bacterial cell wall synthesis. Ceftriaxone inhibits transpeptidase & thus prevents cross linking of bacterial cell wall. Transpeptidase & associated proteins constitute various types of specific binding proteins which have affinity for cephalosporins like Ceftriaxone.

Indications:

  • .Lower respiratory tract infections and community-acquired pneumonia.
  • . Acute bacterial otitis media.
  • . Skin and skin structure infections.
  • . Urinary tract infections.
  • . Uncomplicated gonorrhea.
  • . Pelvic inflammatory disease.
  • . Bacterial septicemia
  • . Intra-abdominal infections.
  • . Bacterial Meningitis.

 

Contact Us
close slider